ARWR vs. SMMT, ACAD, JANX, FOLD, MRUS, MOR, MLTX, IDYA, XENE, and PTCT
Should you be buying Arrowhead Pharmaceuticals stock or one of its competitors? The main competitors of Arrowhead Pharmaceuticals include Summit Therapeutics (SMMT), ACADIA Pharmaceuticals (ACAD), Janux Therapeutics (JANX), Amicus Therapeutics (FOLD), Merus (MRUS), MorphoSys (MOR), MoonLake Immunotherapeutics (MLTX), IDEAYA Biosciences (IDYA), Xenon Pharmaceuticals (XENE), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical preparations" industry.
Summit Therapeutics (NASDAQ:SMMT) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, profitability and community ranking.
Arrowhead Pharmaceuticals received 238 more outperform votes than Summit Therapeutics when rated by MarketBeat users. Likewise, 65.25% of users gave Arrowhead Pharmaceuticals an outperform vote while only 56.91% of users gave Summit Therapeutics an outperform vote.
In the previous week, Summit Therapeutics had 6 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 7 mentions for Summit Therapeutics and 1 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 0.95 beat Summit Therapeutics' score of 0.00 indicating that Summit Therapeutics is being referred to more favorably in the media.
Summit Therapeutics has a net margin of 0.00% compared to Summit Therapeutics' net margin of -163.32%. Summit Therapeutics' return on equity of -90.77% beat Arrowhead Pharmaceuticals' return on equity.
4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 83.7% of Summit Therapeutics shares are held by insiders. Comparatively, 4.5% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Arrowhead Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summit Therapeutics has a beta of -1.13, suggesting that its stock price is 213% less volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500.
Summit Therapeutics currently has a consensus price target of $8.00, suggesting a potential upside of 82.23%. Arrowhead Pharmaceuticals has a consensus price target of $50.80, suggesting a potential upside of 107.86%. Given Summit Therapeutics' higher probable upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Summit Therapeutics.
Summary
Arrowhead Pharmaceuticals beats Summit Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Arrowhead Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARWR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arrowhead Pharmaceuticals Competitors List
Related Companies and Tools
